-transparent.png){kind=logo}
Tolerance of N-2-(p-chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, ITA 104) administered over a 3-month period was studied in a group of healthy volunteers. Acetylsalicylic acid (ASA) was used as a reference drug. Both drugs were administered p.o. at the dose of 1600 mg/d. Plafibride showed a platelet antiaggregant effect similar in intensity to that shown by ASA, but its gastrointestinal tolerance was better. In the same way, plafibride showed a hypolipemic effect which was characterized by a decrease in the plasma level of total lipids and triglycerides and also by a drop in the percentage of the pre-beta-fraction of the lipoproteinogram at the expense of an increase in the alpha-fraction. No rebound effect was noticed when administration of the drug was stopped. The tolerance of plafibride was very good, both from the clinical and analytical point of view.
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
January 1981,
Arzneimittel-Forschung,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
January 1997,
Drugs under experimental and clinical research,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
October 1988,
The Journal of antimicrobial chemotherapy,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
January 1993,
Epilepsia,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
March 1993,
Arzneimittel-Forschung,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
January 1988,
Zhurnal mikrobiologii, epidemiologii i immunobiologii,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
April 1998,
European journal of applied physiology and occupational physiology,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
February 1995,
Arzneimittel-Forschung,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
January 1986,
Indian journal of physiology and pharmacology,
J Dalmau, and
B Vicens, and
J Zapatero, and
L Bruseghini
October 1988,
The Journal of antimicrobial chemotherapy,
